Replies to post #36597 on Humanigen Inc (HGENQ)

[cowtown jay]

The Wainwright analyst I was talking about was Patrick R. Trucchio. And I didn't see VIR get above the $80 range. That seems to happen, when products aren't variant agnostic.

https://thefly.com/landingPageNews.php?id=3418147&headline=VIR;GSK-Vir-Biotechnology-price-target-raised-to--from--at-HC-Wainwright

So there is still a significant unmet need that lenz could fill, if the NIH/NIAID and the FDA can't figure out a way to keep us from penetrating the US market.